Product
ADT
Aliases
ADT (Eligard®*) with or without treatment intensification, ADT (Standard of Care)
5 clinical trials
5 indications
Indication
Prostate CancerIndication
OligometastasisIndication
Oligo-recurrenceIndication
Recurrent Prostate CancerClinical trial
An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate CancerStatus:
Clinical trial
A reAl-World Evidence Study Using Alberta Population Based Data to Describe Treatment Patterns for Metastatic castRation sENsitivE proState Cancer patientS (AWARENESS)Status: Completed, Estimated PCD: 2022-08-16
Clinical trial
An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2028-12-21
Clinical trial
A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesStatus: Completed, Estimated PCD: 2023-10-23
Clinical trial
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)Status: Recruiting, Estimated PCD: 2025-07-01